noci retweeted
2 reliable #biotech quant indicators approaching thresholds from which reversals have occurred.
1- % of Bios within 5% of 52 week lows at 34% is 3rd highest in 3 years, fast approaching the 40% of Oct 2023 important trading low.
2- % of Bios above their 50-DMA at 21% is where short-term reversals occur and closing in on where high probability intermediate upside begins. The elastic band is getting reliably stretched in this baby-out-with-the-bathwater-correlation-approaching-one phase.
noci retweeted
Many said Dupixent would not replace topical steroids…it did.
Most said no one will move beyond topical steroids for Opzelura. Wrong.
Many said Nemluvio couldn’t push Dupixent out at all. It did in itch.
Everyone views current treatments as good enough…until a better treatment comes and then the standard of care becomes neglect of care.
noci retweeted
You mean you don't appreciate when your biotech holding with fantastic data is up 40% in the premarket with 50% more upside to fair value, and then gets crushed to flat at open because risk at a large MM market sold a pod's holdings for blowing up on a MRNA short position, and then a quant momentum strategy shorts it because of the big pullback, and then a quant fund piles on the selling pressure by hedging their AI long trade by shorting interest rate risk out with a SMID cap biotech short, and then the stock is down 15% and no one knows why so an analyst publishes that obviously the stock is down because (pick random datapoint that doesn't matter) but in reality was just persuaded on a call with a pod PM to be bearish because they had a short position they needed to press and then that narrative gets entrenched and you're sitting here wondering why this company swung 60% down on great data and is financed through CF+ and trades at a big discount to some other biotech company and the world moves on to the next company with data tomorrow and no one cares to re-visit your company because it's a "catalyst desert" for 3 months? And pharma then passes over it and buys an undifferentiated pre-clinical private China asset instead of your company, which blows up on them a year later and they write it down but now your company needs to finance at a discount to the prior data?
How could you not love that?
Replying to @pequityresearch
I miss the days when the price discovery was driven by good ol' fashion fundamental analysis.
All quant algos and retail now fucking everything up.
World class biotech rant, mos def candidate for rant of the year. How can something so basic yet so important be such an eternal source of grief. $xbi $abvx $ions $help etc etc
$ABVX $HELP $IONS OK I have to vent a bit. I don't understand how a biotech company can navigate first-in-human clinical trials and yet completely blunder the easiest part: communicating the data effectively in a press release.
You usually have one asset and/or one indication that matters. You have hundreds of millions, sometimes billions, of dollars of cash. You have an investor base with which you are in constant communication. You have sell side analysts who are constantly talking to you and asking you questions from investors that provide you some reference point on what matters to them. You also have an understanding of how your global and site PI have been thinking about the risk/benefit of the product. You also have the benefit of the FDA's communications as well.
You have 3-5 major data updates throughout your lifecycle as a company, from topline data, to updated data, to initial guidance and call on the drug launch, if you aren't acquired before then. These milestones materially impact how the world views the value of your highly speculative asset and company. This asset may have been in development for a decade or more. You've run a clinical trial burning hundreds of millions of dollars of cash to generate the data that proves to the world all of that blood, sweat and tears along the way was worth it and you are one of the few companies that have successfully developed a product that could be a massive commercial success.
And then you dump a steaming hot mess of a press release onto the market right before you plan to raise money. All that time and energy that went into ensuring the trial worked just got partially, or permanently, impaired because no one stepped back and determined what are the most important questions and concerns that an investor would be wondering about, and to address those questions immediately when they are reading the press release to ensure they aren't smashing the sell button before you have a chance to address them. At least halt the stock, that's why that functionality exists.
Let's talk about a few recent ones, starting with the most recent (today): $HELP. Ok, you have fantastic efficacy. That's great. And along the way, you have some SAEs. That's ok, lots of drugs have SAEs, and they will be weighed against your great efficacy. Even better, your SAE's look like they may actually just be manifestation of the underlying symptoms of the disease (i.e. depression and suicidal ideation). So who in the world thought it was a good idea to identify these SAEs as treatment-related, then leave it to the reader's imagination on the nature of these SAEs while the stock was unhalted???
Are these patients even still alive? You could have not disclosed them in the PR and disclosed all the detail in the presentation, and have been fine. You could have disclosed them in the PR and provided detail to help investors understand that these weren't catastrophic in nature. And yet you willingly did neither. And now you've created new narrative overhangs that have emerged in order to explain the share price movement even after it is disclosed the SAEs were not only common with this indication, but were one of the primary symptom manifestations of the underlying disease.
I have shorts over here that will try to hide Grade 5 liver toxicity events by not disclosing them and claiming they hadn't yet ruled out that the late 39 y.o. former physician didn't take up wild mushroom eating during his time on the trial, and yet longs will just throw out "oh yeah, there were a few serious drug-induced events but we aren't disclosing what they are...usually a bad sign right?? Just wait until we reveal to you what these things are...did they make our efficacy completely irrelevant?? Take a guess!" and then later on give details that made me question why in the world they would not have given that detail earlier before people obliterated their share price.
$IONS was another great example. sHTG was the only thing that really mattered this recent earnings. Their initial guide earlier this year was bizarrely high, then they guide down and provide no useful metrics to immediately understand that the launch is actually doing ok. Instead, we get a Rubik's Cube of select random datapoints that I have to make assumptions around to back into what the launch looks like, only to realize they've now completely swung the pendulum in the other direction and guided to a number that makes it seem to anyone looking at it at surface level like they're not going to get another incremental patient on drug in 4Q, rather just run-rate their prior quarter in patients. Every other company gives start forms, why am I having to back into projecting what I think are decent enough revs based on a mix of lives covered, % of physicians who prescribed drug to more than one patient, net pricing, assumptions on prior indication growth, and percentage of physicians who ate ham sandwiches while placing an order for the drug in their EMR?
$ABVX We've beaten this dead horse enough. But the list wouldn't be credible if it didn't exist on it.
I have offered to go under CDA and restrict myself to help companies I own to provide feedback on how to effectively communicate press release data, but the number of companies who take me up on it are quite small. Worse over, I know of instances where top holders will consult with the company in such a matter, and yet the PR is still a mess.
If your company is a 10% position in my fund, I'm going to care a LOT about how that press release is written, even if notionally I'm less than a large fund's holdings. If you are a .5% to 2% position, the incentive to really dig in and think about all ways that communication could fail is much smaller than mine.
Please stop screwing up the easiest part of drug development -- the promotion of your own asset, and relying on people to figure it out on their own. You'll find that in an era of increasingly short term horizon investors, the mistake may have more permanent consequences than ever before. And then pharma looks at the share price movement, reads the same PR, and comes to the same wrong conclusion about the reality of the situation.
9
1,353
noci retweeted
$ABVX $HELP $IONS OK I have to vent a bit. I don't understand how a biotech company can navigate first-in-human clinical trials and yet completely blunder the easiest part: communicating the data effectively in a press release.
You usually have one asset and/or one indication that matters. You have hundreds of millions, sometimes billions, of dollars of cash. You have an investor base with which you are in constant communication. You have sell side analysts who are constantly talking to you and asking you questions from investors that provide you some reference point on what matters to them. You also have an understanding of how your global and site PI have been thinking about the risk/benefit of the product. You also have the benefit of the FDA's communications as well.
You have 3-5 major data updates throughout your lifecycle as a company, from topline data, to updated data, to initial guidance and call on the drug launch, if you aren't acquired before then. These milestones materially impact how the world views the value of your highly speculative asset and company. This asset may have been in development for a decade or more. You've run a clinical trial burning hundreds of millions of dollars of cash to generate the data that proves to the world all of that blood, sweat and tears along the way was worth it and you are one of the few companies that have successfully developed a product that could be a massive commercial success.
And then you dump a steaming hot mess of a press release onto the market right before you plan to raise money. All that time and energy that went into ensuring the trial worked just got partially, or permanently, impaired because no one stepped back and determined what are the most important questions and concerns that an investor would be wondering about, and to address those questions immediately when they are reading the press release to ensure they aren't smashing the sell button before you have a chance to address them. At least halt the stock, that's why that functionality exists.
Let's talk about a few recent ones, starting with the most recent (today): $HELP. Ok, you have fantastic efficacy. That's great. And along the way, you have some SAEs. That's ok, lots of drugs have SAEs, and they will be weighed against your great efficacy. Even better, your SAE's look like they may actually just be manifestation of the underlying symptoms of the disease (i.e. depression and suicidal ideation). So who in the world thought it was a good idea to identify these SAEs as treatment-related, then leave it to the reader's imagination on the nature of these SAEs while the stock was unhalted???
Are these patients even still alive? You could have not disclosed them in the PR and disclosed all the detail in the presentation, and have been fine. You could have disclosed them in the PR and provided detail to help investors understand that these weren't catastrophic in nature. And yet you willingly did neither. And now you've created new narrative overhangs that have emerged in order to explain the share price movement even after it is disclosed the SAEs were not only common with this indication, but were one of the primary symptom manifestations of the underlying disease.
I have shorts over here that will try to hide Grade 5 liver toxicity events by not disclosing them and claiming they hadn't yet ruled out that the late 39 y.o. former physician didn't take up wild mushroom eating during his time on the trial, and yet longs will just throw out "oh yeah, there were a few serious drug-induced events but we aren't disclosing what they are...usually a bad sign right?? Just wait until we reveal to you what these things are...did they make our efficacy completely irrelevant?? Take a guess!" and then later on give details that made me question why in the world they would not have given that detail earlier before people obliterated their share price.
$IONS was another great example. sHTG was the only thing that really mattered this recent earnings. Their initial guide earlier this year was bizarrely high, then they guide down and provide no useful metrics to immediately understand that the launch is actually doing ok. Instead, we get a Rubik's Cube of select random datapoints that I have to make assumptions around to back into what the launch looks like, only to realize they've now completely swung the pendulum in the other direction and guided to a number that makes it seem to anyone looking at it at surface level like they're not going to get another incremental patient on drug in 4Q, rather just run-rate their prior quarter in patients. Every other company gives start forms, why am I having to back into projecting what I think are decent enough revs based on a mix of lives covered, % of physicians who prescribed drug to more than one patient, net pricing, assumptions on prior indication growth, and percentage of physicians who ate ham sandwiches while placing an order for the drug in their EMR?
$ABVX We've beaten this dead horse enough. But the list wouldn't be credible if it didn't exist on it.
I have offered to go under CDA and restrict myself to help companies I own to provide feedback on how to effectively communicate press release data, but the number of companies who take me up on it are quite small. Worse over, I know of instances where top holders will consult with the company in such a matter, and yet the PR is still a mess.
If your company is a 10% position in my fund, I'm going to care a LOT about how that press release is written, even if notionally I'm less than a large fund's holdings. If you are a .5% to 2% position, the incentive to really dig in and think about all ways that communication could fail is much smaller than mine.
Please stop screwing up the easiest part of drug development -- the promotion of your own asset, and relying on people to figure it out on their own. You'll find that in an era of increasingly short term horizon investors, the mistake may have more permanent consequences than ever before. And then pharma looks at the share price movement, reads the same PR, and comes to the same wrong conclusion about the reality of the situation.
noci retweeted
With Iñárritu's DIGGER (2026) struggling to recover its budget at the box office, here's a reminder that some of cinema's greatest masterpieces were once commercial failures.
noci retweeted
16 big pharmas. 2,000+ M&A comments since 2024.
Where they said they were looking vs. where they’re looking now.
The stage split: Sanofi, BMS and Regeneron are now open to commercial-stage assets. Biogen, Pfizer and Amgen moved earlier, toward Phase 1–2 and platforms.
China is now a named deal source for 11 of 16.
Immunology is being carved up by sub-area: IBD combinations (Gilead, Merck, AbbVie), dermatology and respiratory (Sanofi, AbbVie, GSK), and in vivo CAR-T and immune reset (Lilly, J&J, BMS).
The obesity buyers have mostly bought. Novo says obesity is no longer at the front of its BD, and AbbVie wants a partner drug for its amylin.
1. Sanofi set up a big late-stage deal in one quarter. Oct 30 is the sharpest pivot in the set.
Stage: “early, early” deals became “later-stage commercial assets”.
Urgency: “not chasing growth” became Dupixent’s loss of exclusivity as the “top priority”.
Areas: neurology was dropped, and non-core areas may be out-licensed.
Firepower: EUR 15B+ became “not in a position to give you an amount”.
Rating: “AA” became “strong investment-grade”, with external financing mentioned.
Hint: refusing to size firepower while loosening the rating language buys room for something bigger than EUR 15B, possibly debt-funded. The mid-December update is the tell, and they said a deal “can be communicated at any time before”.
2. Vertex’s “no change” lasted five weeks. Asked on May 29 whether its appetite for bigger deals was changing, the CEO said “No”. On July 6 it agreed to buy Crinetics for about $10B, its first debt-funded deal, double its previous record. It bought before Phase 3 data because it “didn’t want to wait… or potentially see another bidder”.
Hint: a company’s denials about deal appetite are weak evidence. Watch what it pays, not what it says.
3. Gilead says “no more deals this year”, then keeps dealing, and cash returns are slipping. In August it said it did “not currently anticipate pursuing additional sizable M&A transactions this year”. By Q4 it had $1.4B of new upfronts, including an oral IL-23R for IBD. Shareholder returns ran about 40% of free cash flow through Q3, against an “at least 50%” commitment. It also admitted a 2027–29 pipeline gap after saying in 2024 “we have what we need”.
Hint: deal spending is crowding out shareholder returns.
4. Merck’s urgency drained out.
Language: “top priority… with urgency” (Q3 2025) became “We are not desperate to do any deal”.
The script: BD slipped from “high priority” to “important priority”, and the CEO’s prepared remarks didn’t mention it.
Size: going above $15B is now “harder”.
Hint: after Verona, Cidara and Terns, Merck is digesting. A mega-deal looks less likely now than a year ago.
5. Lilly is moving cash from buybacks into risk.
Capital: buybacks fell from $2.4B in Q1 to $0.4B in Q3, while acquired IPR&D hit $4.57 a share, against $0.71 a year earlier.
Cell therapy: from “nothing going on in cell therapy” (2024) to in vivo CAR-T as “a huge opportunity”.
Neuroscience: an explicit build into sleep, psychiatry and pain.
Scope: BD is now “not solving for any one given therapeutic area”.
Hint: the incretin cash machine is funding the most aggressive diversification in the group. Dec 7 is likely where Lilly frames it.
6. Novo narrowed on size but widened on areas.
Size: “$20–40B, we could afford it” (January) became bolt-ons only.
Areas: “we are really good when we focus” became new Blood & Endocrine, Liver and Cardiovascular segments, plus Consumer Rx, pain and addiction, and women’s and men’s health.
Obesity: BD there is “not at the forefront”.
Hint: expect many small deals outside obesity, sourced partly from China, rather than one big one.
7. Biogen reversed its stage preference within eight months. In early 2026 it wanted Phase 3 or launched assets up to about $5–6B; now it “always hated having to go buy assets in later stage” and wants development candidate to Phase 1b.
Hint: Apellis filled the near-term gap. Biogen is out of the late-stage bidding pool until its debt is paid down at the end of 2027.
8. Regeneron contradicted itself on deal rationale. In March 2026 IR said M&A would never be driven by commercial synergy; on Oct 30 using its commercial reach is a stated criterion. At the same time it calls itself a “net out-licensor of innovation” after handing four antibodies to the Sanofi alliance, and it says “No aversion whatsoever” to a deal of size.
Hint: it’s openly hunting a commercial-stage asset and repeatedly says it lost auctions on price. That makes it the most likely surprise buyer among the “not done anything big” names.
9. AbbVie signaled an obesity partnership. After Apogee it says “more bolt-on additions. Versus a large transformational deal like Allergan”, but its CSO is now open to a partner drug, possibly from the incretin class, to co-formulate with its amylin drug.
Hint: watch for an incretin licensing deal rather than an acquisition.
10. Smaller tells worth noting:
J&J: the CEO says of the AAA rating, “We are not married to that”. GLP-1s and pulmonary hypertension are explicitly off the table, and its 2030 target assumes no deals.
Takeda: it said nothing about BD on its Oct 29 call. Strategy is deferred to the Dec 11 Capital Markets Day.
AstraZeneca: it says it prefers early-stage deals, yet every 2026 deal was late-stage or commercial and sourced from China. Soriot floated an Alexion-size 10–20B deal, “even 20–30B”.
Pfizer: it now flags political risk from Beijing as well as Washington while calling China its main source of deals.
In mice.
Scientists found a way to flush Alzheimer’s plaque out of the brain in minutes.
Without any surgery and drugs.
Your brain has a waste-clearance network called the glymphatic system. It flushes out toxic proteins and dead cells.
But it only really activates during deep, slow-wave sleep.
If you don't sleep, the trash piles up. Over time, that buildup leads to cognitive decline and Alzheimer's.
Until today.
Researchers just published a paper proving they can manually trigger this cleaning cycle.
Without you ever going to sleep.
They used 40.68 MHz ultrashort waves (USW) beamed non-invasively into the brain.
Within 10 minutes, the brain's fluid flow rapidly accelerated.
The waves artificially synchronized the neurons into a Delta state, the exact frequency of deep sleep. This forced the brain's water channels to open and start flushing out the system.
They tested it on mice with traumatic brain injuries and Alzheimer's pathology.
The brain swelling dropped. The toxic proteins were cleared out. Cognitive deficits actually improved.
No surgery. No massive chemical interventions. Just a frequency.
2
574


































